Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
Featured news and events
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
ADI's Global Perspective for July 2020 now available.
The German Government announces that a national dementia strategy has been officially adopted.
Alzheimer’s Disease International (ADI) and ITN Productions have co-produced a new documentary ‘Hope in the Age of Dementia'.
The following piece is from our third 'From Plan to Impact' report and written by ADI's Communications and Policy Manager, Annie Bliss, the main author of the report. In this piece, she writes about the impact of the COVID-19 pandemic on diagnostic, treatment, care and support services for people living with dementia.
A new report by ADI calls on world governments to ensure that dementia remains a priority during and after the COVID-19 pandemic.
Catherine Hall, Chief Executive of Alzheimers New Zealand, writes about how Alzheimers New Zealand has responded and adapted to COVID-19, both in the first weeks of lockdown and today.
Alzheimer’s Disease International (ADI) and partner Dementia Alliance International (DAI) join other civil society organisations in a statement to the World Health Organization (WHO).
In advance of the 73rd World Health Assembly, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.